Myriad Genetics, Inc.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company headquartered in Salt Lake City, Utah, United States. The company's core mission is to advance health and well-being by empowering individuals and healthcare providers with genetic insights to better detect, treat, and prevent disease.

Myriad Genetics develops and commercializes a comprehensive portfolio of molecular diagnostic tests across various medical specialties. Key product areas include hereditary cancer risk assessment (e.g., MyRisk Hereditary Cancer, BRACAnalysis), tumor profiling (e.g., MyChoice CDx, Prolaris for prostate cancer), prenatal screening (e.g., Foresight, Prequel), and pharmacogenomics (e.g., GeneSight for mental health medications). These tests are designed to assess an individual's risk for developing disease, predict disease progression, guide treatment decisions, and identify a patient's likelihood of responding to specific drug therapies.

Under the leadership of President and CEO Sam Raha, Myriad Genetics is strategically focused on its Cancer Care Continuum to drive accelerated growth, expanding its test portfolio into areas such as therapy selection and Molecular Residual Disease (MRD) testing. The company reported full-year 2025 revenue of $824.5 million and has projected revenues between $860 million and $880 million for 2026, with plans for new product launches in 2026, including an AI-enabled Prolaris test and Precise MRD.